The Telehealth Brands Most Likely to Pivot Into Peptides After PCAC

The companies best positioned to capture the peptide category after the July PCAC outcome are the direct-to-consumer telehealth brands that built their infrastructure around GLP-1 prescribing over the past three years. They have the prescriber networks, the compounding pharmacy relationships, the insurance-independent revenue model, and the performance-marketing machinery to move into peptides faster than any other market participant.

PeptidesBeat has identified the telehealth operators most actively preparing for a peptide-category expansion. Without naming specific companies (several declined to comment on background, and internal hiring signals do not constitute announced pivots), the pattern is clear: direct-to-consumer telehealth will be the dominant retail channel for compounded peptides by the end of 2026.

What this means for pricing. Telehealth brand economics compress margins relative to traditional pharmacy pricing. First-order promotional pricing for BPC-157 and GHK-Cu from a major telehealth brand by Q4 2026 is expected in the $60–$90 per 5mg vial range, well below the $100–$200 range expected from standalone compounding pharmacies.

What this means for quality. Telehealth brands are not quality-guaranteed. The same company can source from a PCAB-accredited compounder or a low-bidder with minimal transparency — the brand name reveals nothing about the underlying compounder. The 10-point pharmacy checklist applies whether you are ordering from a retail compounder directly or through a telehealth brand.

What this means for prescriber relationships. Telehealth prescribing for peptides will function similarly to telehealth prescribing for GLP-1s: asynchronous questionnaire-based intake, limited clinical follow-up, and monitoring protocols that vary widely by operator. For simple indications, this model works. For complex indications, an established in-person prescriber relationship remains preferable.

What to watch in the next 90 days. Post-PCAC, watch for telehealth brand announcements in August and September that include specific peptides in their formularies, credentialing announcements for peptide-trained medical directors, and partnership announcements with named compounding pharmacies. Those signals mark the transition from early-mover market to mass-market retail. ���